オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - dasatinib, quantity: 100 mg - tablet, film coated - excipient ingredients: hyprolose; lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; triacetin - dasatinib is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fenofibrate, quantity: 145 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; hypromellose; magnesium stearate; croscarmellose sodium; sucrose; microcrystalline cellulose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - fenofibrate sandoz is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia; - types ii, iii, iv and v dyslipidaemia; - dyslipidaemia associated with type 2 diabetes. fenofibrate sandoz is indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy. fenofibrate sandoz does not replace the appropriate control of blood pressure, blood glucose and blood lipids in reducing the progression of diabetic retinopathy.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 33 mg (equivalent: cinacalcet, qty 30 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; hyprolose; microcrystalline cellulose; crospovidone; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 99 mg (equivalent: cinacalcet, qty 90 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; hyprolose; crospovidone; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 33 mg (equivalent: cinacalcet, qty 30 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; crospovidone; microcrystalline cellulose; hyprolose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 99 mg (equivalent: cinacalcet, qty 90 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; hyprolose; crospovidone; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 66 mg (equivalent: cinacalcet, qty 60 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; hyprolose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cinacalcet hydrochloride, quantity: 66 mg (equivalent: cinacalcet, qty 60 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; hyprolose; crospovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. cinacalcet should be used as adjunctive therapy. ,cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma. ,cinacalcet may be used to treat the biochemical manifestations of primary hyperparathyroidism in patients for whom parathyroidectomy is not a treatment option.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - gilteritinib fumarate, quantity: 44.2 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; mannitol; titanium dioxide; macrogol 8000; hypromellose; purified talc; iron oxide yellow - xospata is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (aml) with a flt3 mutation.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - asciminib hydrochloride, quantity: 43.24 mg (equivalent: asciminib, qty 40 mg) - tablet, film coated - excipient ingredients: polyvinyl alcohol; lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; iron oxide black; hyprolose; lecithin; titanium dioxide; iron oxide red; xanthan gum; purified talc - scemblix is indicated for the treatment of patients 18 years of age and above with: ? philadelphia chromosome-positive chronic myeloid leukaemia (ph+ cml) in chronic phase (cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.1 clinical trials). ? ph+ cml in cp with the t315i mutation.